Cypark is the most undervalued renewable energy stock

Revenue new high

If forward PE 10 then share price will be 49 Sen. Good result

Will wake up in 2021

Ally, please add me into your discussion group. Thank You.

good result

Ally, kindly add me. Thanks

Hi Ally. Please PM me. Thanks

Moreover giving 3 sen dividend ex in November

Prospects remain bright. Profit margin dropped to 19.3% due to increase in expenditure for local and overseas expansion. The company is confident that it can do well next q and in 2021.

Agree with Thelastone and Grova1. Don't just look at current PE. with double digit growth, ROE 28, excellent profit margin, with orderbook of 295 million, estimated eps next 2 Q is 3.5 to 4 sen per quarter. This will be even higher for 2021. Good prospects.

Karim bought back!

Dropped more, rebound more.

Oversold. Buy tomorrow.

It's OK because Karim sold kpower and scib to buy and support serbadk share price

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)316...

Conclusion from Lancet publication (4/9/2020):
In conclusion, ChAdOx1 nCoV-19 was safe, tolerated, and immunogenic, while reactogenicity was reduced with paracetamol. A single dose elicited both humoral and cellular responses against SARS-CoV-2, with a booster immunisation augmenting neutralising antibody titres.

Lancet is a internationally renowned medical journal. An effective and safe vaccine is in no time, promising and very soon.

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)316...

Conclusion from Lancet publication (4/9/2020):
In conclusion, ChAdOx1 nCoV-19 was safe, tolerated, and immunogenic, while reactogenicity was reduced with paracetamol. A single dose elicited both humoral and cellular responses against SARS-CoV-2, with a booster immunisation augmenting neutralising antibody titres.

Lancet is a internationally renowned medical journal. An effective and safe vaccine is in no time, promising and very soon.

Suprnoob, it depends on government policy. Preferably the whole population of Malaysia get vaccinated but the supply won't be able to meet the demand initially. So as a start maybe the health care personnel will get the vaccine first, followed by those above 50 to 60 years old (because they are more serious if infected with covid), then only all other groups. At least 2 jabs are needed to boost the immunity. The vaccines likely can cover for mutant strains as well.
Please refer to: Vaccine candidates likely remain effective against mutations, By Leng Shumei and Hu Yuwei Source: Global Times Published: 2020/8/17

RMCO extension will not affect duopharma and pharma because all the phamaceutical business has resumed normally.

China produced vaccines no need to get FDA approval.

I also bought at about 52 Sen. I wonder to keep for rights issues or sell? Any catalyst for further upside?

https://www.klsescreener.com/v2/news/view/715591
Result is commendable.

Good result. PE only 12.79. Still cheap.

Need to wear glove when administering Covid vaccines, but not necessary for health personnels to change gloves after each injection because people eligible for vaccines are those who are not having covid.

People will look beyond Q2. Don’t worry about poor Q2 result

If flu vaccine can be made many years ago why covid vaccine not possible?

Lots of work to do first year 34mx2 doses and subsequently at least 34m doses (Malaysia population) annually! Great expansion needed for duopharma if that situation happens!

After buying vaccines in bulk from China, they need to have Tech Transfer to local pharma to continue producing covid vaccine continuously and annually

Maybe just like flu vaccine which need to jab yearly. Like that demand is great and continuous. Good for duopharma!

Still can earn 1.19 Sen considered quite good. Some more got 2 Sen dividend. Not bad.

Good chance to top up with its share price suppressed

Please add me. Thanks

Going towards RM1 next week

I thought one week ago KYY asked people not to sell Dayang as it was uptrending?

switch to Ornapaper

Ornapaper is better

Buy

Naim should not drop much as it didn't go up crazy like dayang. Moreover its construction and property segments should generate good profit.

Uptrending

Result is good. PE only 5.8. ROE 19, dividend 5%

Agree that the fatality rate is much less than 2%,because the denominator is greatly under-reported. Many minor cases may not seek treatment and just stay at home and they recover spontaneously.

Naim is doing catch-up and should have more upside too

Bonus coming?

Based on the fact that Naim holds 26% of Dayang shares, with Dayang share price now RM2.90 , by calculation, the market value of Naim is RM1.586 just by holding Dayang shares alone. Naim PE is only 7.24, if we value it at PE 10, Naim should worth at least RM 1.75

Naim very bullish

Very good. Up despite poor market sentiment

Teoseng is the best among all

Based on the fact that Naim holds 26% of Dayang shares, by calculation, the market value of Naim is RM1.32 just by holding Dayang shares alone

Just need some patience for it to go up

Trading within tight range. Will shoot up soon